Some patients ultimately diagnosed with primary CNS lymphoma (PCNSL) have transient symptomatic contrast enhancing lesions. These "sentinel lesions" of PCNSL recede spontaneously or with corticosteroid treatment and present an important diagnostic dilemma because they show variable, but non-diagnostic histopathological features.
Abstract
Some patients ultimately diagnosed with primary CNS lymphoma (PCNSL) have transient symptomatic contrast enhancing lesions. These "sentinel lesions" of PCNSL recede spontaneously or with corticosteroid treatment and present an important diagnostic dilemma because they show variable, but non-diagnostic histopathological features.
Four previously healthy, immunocompetent patients aged 49 to 58 years had contrast enhancing intraparenchymal brain lesions. Before biopsy, three of the four were treated with corticosteroids. Initial biopsies showed demyelination with axonal sparing in two, non-specific inflammation in one, and normal brain in one. Infiltrating lymphocytes predominantly expressed T cell markers with rare B cells. All four patients recovered within two to four weeks after the initial biopsy and imaging studies showed resolution of the lesions. The CSF was normal in three of the four patients tested; oligoclonal bands were absent in both of the two tested.
After seven to 11 months, each patient developed new symptomatic lesions in a different region of the brain, biopsy of which showed a B cell PCNSL. The mechanism of spontaneous involution of sentinal lesions is not In November 1989, 11 months after her initial symptoms, she had five weeks of progressive headache, confusion, and dysarthria. A contrast enhancing lesion was seen in the right frontal lobe on CT and MRI. A CT guided biopsy disclosed a B cell lymphoma of the diffuse large cell subtype. Serology for HIV was negative.
Patient 3 A 54 year old woman noted headache, right arm weakness, and dysarthria in April 1992. Brain CT and MRI showed an enhancing lesion in the left internal capsule ( fig 1A) and she was started on phenytoin and dexamethasone. Serology for HIV was negative. Stereotactic biopsy of the involved white matter performed one week later showed perivascular inflammatory cells and hypertrophic astrocytes. Immunostaining with Leu22, UCHL1, 4KB5, L26, and S100 showed mostly T cells and macrophages with rare B cells. She improved clinically over the following next two weeks and the medications were discontinued. Brain MRI in May 1992 showed resolution of the lesion (fig 1 B) and neurological examination was normal. In January 1993 she developed a left hemiparesis and MRI showed a right internal capsule lesion with small satellite lesions in the periventricular white matter (fig  1 C) . Biopsy of the new lesion disclosed a malignant B cell lymphoma of the diffuse large cell subtype. Patient 4 This 57 year old woman developed dysarthria and numbness in her right face and hand in November 1987. A contrast enhancing mass in the left parietal lobe was evident on CT and MRI showed this lesion as well as an area of increased signal on T2 in the right occipital lobe. She was treated with dexamethasone (6 mg/day) for two weeks before admission. Biopsy of the parietal lesion showed destruction of myelin with axonal sparing, many T lymphocytes and foamy macrophages, rare B cells, and no evidence of neoplasm (fig 2) . A diagnosis of probable multiple sclerosis was made and she was treated with a brief course of corticosteroids. Her symptoms resolved over two weeks and CT in April 1988 was Despite the varied pathological appearance of the lesions, the clinical syndrome of sentinel lesions is remarkably consistent. All patients had contrast enhancing lesions that looked like brain tumours, but regressed either with corticosteroids or spontaneously. Our experience with the first patients with this syndrome led us to tell patient 3 after her initial non-diagnostic biopsy that we were concerned about the diagnosis of PCNSL. We advised close clinical and radiographic follow up. Despite careful surveillance for recurrence, when the second focus of tumour appeared, it progressed rapidly, and a severe hemiparesis developed within days. This explosive course suggests reactivation of disease in another site, rather than an indolent lesion detected when it reached a critical size.
The seven to 11 month interval between sentinel and diagnostic biopsies in these four patients was relatively consistent. It is possible that lymphoma is kept dormant by host immunity. In a mouse model of systemic lymphoma, a prolonged dormant period can be induced with passive immunity to the tumorigenic B cells." In molecular analysis of recurrent systemic B cell tumours, the immunoglobulin genes in a neoplastic clone continuously undergo mutation, eventually escaping autoimmune tumour destruction.'2 PCNSL may be a multifocal disease from the onset, and the latency between the first and second tumours could be the time taken for another neoplastic clone to emerge.
It is important to stress the fact that the diagnosis of "sentinel lesions" can be suspected on clinical grounds. When a patient 50 years or older has a contrast enhancing focal lesion, even if the biopsy shows demyelinating changes, the diagnosis of PCNSL should be seriously considered. This should lead to changes in management including early discontinuation of corticosteroids, repeat biopsy (in certain instances), and close clinical and radiographic surveillance of the patient. The main differential diagnosis is multiple sclerosis which is often treated with long term corticosteroid therapy or immunosuppressive therapy that would likely obscure or delay the correct diagnosis. Admittedly, even with careful monitoring, patients do develop recurrent tumour that may be resistant to therapy; however, early diagnosis and treatment will still afford the best prognosis.
